<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty-eight patients with moderate (n = 15) or severe (n = 53) <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> were entered into a prospective, randomized, two-arm treatment study comparing antihuman thymocyte globulin (ATG), lower-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> (LDM) and oxymetholone to ATG, higher-dose <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> (HDM), and oxymetholone </plain></SENT>
<SENT sid="1" pm="."><plain>There were no differences between the two groups when comparing age, sex, etiology of <z:mpath ids='MPATH_58'>aplasia</z:mpath>, disease duration, severity of <z:mpath ids='MPATH_58'>aplasia</z:mpath>, or pretherapy granulocyte counts </plain></SENT>
<SENT sid="2" pm="."><plain>Side effects of LDM and HDM were similar </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 64 patients evaluable for response to therapy, 12 of 33 (36%) who received LDM had complete, partial, or minimal responses compared with 15 of 31 patients (48%) who received HDM (P = .33) </plain></SENT>
<SENT sid="4" pm="."><plain>Actuarial survival at 4 years is 43% for patients in the LDM group and 47% for patients in the HDM group (P = .99) </plain></SENT>
<SENT sid="5" pm="."><plain>Causes of <z:hpo ids='HP_0011420'>death</z:hpo> included <z:mp ids='MP_0001914'>hemorrhage</z:mp>, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, evolution to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, and complications of subsequent bone marrow transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>Long-term complications included <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (n = 3), evolution to <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (n = 6), and recurrent <z:mpath ids='MPATH_58'>aplasia</z:mpath> (n = 6) </plain></SENT>
<SENT sid="7" pm="."><plain>We were unable to show a significant difference in toxicity, response rate, or survival for patients treated with ATG, oxymetholone, and LDM compared with patients who received ATG, oxymetholone, and HDM </plain></SENT>
</text></document>